Alpha 2.0
Login Register
» Authors » Francois Laliberte

Francois Laliberte

Explore the profile of Francois Laliberte including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 131
Citations 1054
Followers 0
Related Specialties
Pharmacology
Oncology
General Medicine
Top 10 Co-Authors
Patrick Lefebvre
Guillaume Germain
Mei Sheng Duh
Dominique Lejeune
Concetta Crivera
Jeff Schein
Winnie W Nelson
Sean D MacKnight
Veronica Ashton
Dominic Pilon
Published In
J Med Econ
Curr Med Res Opin
Adv Ther
Int J Chron Obstruct Pulmon Dis
Future Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States
Masand P, Parikh M, Ta J, Zanardo E, Lejeune D, Martinez C, et al.
J Med Econ . 2025 Feb; 28(1):335-345. PMID: 39969410
Aim: To compare all-cause and mental health (MH)-related short-term and long-term disability leaves and associated costs among patients in the United States with bipolar disorder (BP), major depressive disorder (MDD),...
2.
Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting
Correll C, Cutler A, Laliberte F, Germain G, MacKnight S, Boudreau J, et al.
Ann Gen Psychiatry . 2025 Jan; 24(1):5. PMID: 39871357
Background: Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from...
3.
Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA
Settipane R, Germain G, Laliberte F, Mahendran M, Hilts A, Duh M, et al.
Pulm Ther . 2025 Jan; 11(1):81-100. PMID: 39869154
Introduction: Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β-agonist; however, characterization of elderly...
4.
Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder
Masand P, Clayton A, Parikh M, Laliberte F, Germain G, Mahendran M, et al.
J Med Econ . 2025 Jan; 28(1):235-244. PMID: 39841541
Aim: Inadequate response to antidepressant therapy (ADT) is common in major depressive disorder (MDD); atypical antipsychotic (AA) adjunctive therapy may be effective for these patients. This study aimed to compare...
5.
Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease
Mannino D, Weng S, Germain G, Boudreau J, Tardif-Samson A, Forero-Schwanhaeuser S, et al.
Adv Ther . 2024 Dec; 42(2):1131-1146. PMID: 39731707
Introduction: Chronic obstructive pulmonary disease (COPD) is associated with exacerbations which can reduce quality of life and increase mortality. Single-inhaler triple therapy (SITT) is recommended for maintenance treatment of COPD...
6.
Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Baptist A, Germain G, Klimek J, Laliberte F, Schell R, Forero-Schwanhaeuser S, et al.
Adv Ther . 2024 Dec; 42(2):1061-1074. PMID: 39714547
Introduction: The clinical benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) have been demonstrated in clinical trials. There is limited evidence regarding the effectiveness and economic outcomes associated with FF/UMEC/VI use in US...
7.
Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data
Young C, Lee L, DiRocco K, Germain G, Klimek J, Laliberte F, et al.
Adv Ther . 2024 Dec; 42(2):830-848. PMID: 39636563
Introduction: Previously, adherence and persistence to treatment have been shown to improve outcomes among patients with chronic obstructive pulmonary disease (COPD). This study aimed to evaluate adherence and persistence to...
8.
Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States
Mathur S, Silver J, MacKnight S, Urosevic A, Martinez C, Zhang K, et al.
Ann Allergy Asthma Immunol . 2024 Nov; 134(3):341-350.e2. PMID: 39549986
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, chronic inflammatory disease characterized by asthma and small/medium vessel vasculitis. Mepolizumab is approved for use in EGPA disease management alongside oral...
9.
Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder
Cutler A, Laliberte F, Germain G, MacKnight S, Boudreau J, Wade S, et al.
J Med Econ . 2024 Nov; 27(1):1472-1484. PMID: 39531329
Aims: To evaluate the healthcare resource utilization (HRU) and costs of patients who initiated cariprazine as their first versus subsequent atypical antipsychotic (AA) following a bipolar I disorder (BP-I) diagnosis....
10.
Pre-Exposure Prophylaxis for the Prevention of HIV-1: An Assessment of Oral Pre-Exposure Prophylaxis Usage Patterns, First Evidence of HIV-1, and HIV-1 Risk Factors in the United States
Oglesby A, Germain G, Metzner A, Laliberte F, MacKnight S, Hilts A, et al.
AIDS Patient Care STDS . 2024 Nov; 38(11):495-506. PMID: 39506929
In clinical trials, once-daily oral tenofovir-based pre-exposure prophylaxis (PrEP) significantly reduced HIV-1 acquisition risk; however, this was highly dependent on medication adherence and persistence. We report clinical characteristics, PrEP usage...